Your browser doesn't support javascript.
loading
Denosumab-treated giant cell tumor of bone. Its histologic spectrum and potential diagnostic pitfalls.
Roitman, Pablo Daniel; Jauk, Federico; Farfalli, Germán Luis; Albergo, José Ignacio; Aponte-Tinao, Luis Alberto.
Afiliación
  • Roitman PD; Pathology Department, Italian Hospital of Buenos Aires, 1199 Buenos Aires, Argentina. Electronic address: pablo.roitman@hospitalitaliano.org.ar.
  • Jauk F; Pathology Department, Italian Hospital of Buenos Aires, 1199 Buenos Aires, Argentina.
  • Farfalli GL; Institute of Orthopedics "Carlos E. Ottolenghi,", Italian Hospital of Buenos Aires, 1199 Buenos Aires, Argentina.
  • Albergo JI; Institute of Orthopedics "Carlos E. Ottolenghi,", Italian Hospital of Buenos Aires, 1199 Buenos Aires, Argentina.
  • Aponte-Tinao LA; Institute of Orthopedics "Carlos E. Ottolenghi,", Italian Hospital of Buenos Aires, 1199 Buenos Aires, Argentina.
Hum Pathol ; 63: 89-97, 2017 05.
Article en En | MEDLINE | ID: mdl-28235628
Giant cell tumor (GCT) of bone is a locally aggressive, rarely metastasizing primary bone neoplasm that occurs most frequently in the epiphysis of long bones of young adults. It is composed of round, oval, or elongated mononuclear cells admixed with osteoclast-like giant cells that express receptor activator of nuclear factor κB (RANK). The mononuclear stromal cells express RANK ligand, a mediator of osteoclast activation. Denosumab, a monoclonal antibody that reduces tumor associated bone lysis by inhibiting the action of RANK ligand, has been used to treat selected cases of GCT. We reviewed the clinical records and histologic slides of 9 patients with GCT who had received denosumab therapy and were subsequently surgically treated. There were 5 men and 4 women aged 20 to 66 years (mean, 36 years). Duration of treatment varied from 2.5 to 13months (mean, 5.9 months). In all cases, different degrees of ossification, fibrosis, depletion of giant cells, and proliferation of mononuclear cells were seen. With this combination of changes, denosumab-treated GCT may mimic other lesions such as fibrous dysplasia, juvenile ossifying fibroma, nonossifying fibroma, and osteoblastoma. Less frequent but more relevant is the presence of cellular atypia or patterns of ossification that resemble an undifferentiated pleomorphic sarcoma, a conventional osteosarcoma, or a low-grade central osteosarcoma. The presence of clinical and radiologic response to denosumab, along with the lack of high mitotic activity, atypical mitotic figures, extensive necrosis, or a permeative pattern of growth, represents clues to achieve a correct diagnosis.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Tumor Óseo de Células Gigantes / Denosumab / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hum Pathol Asunto de la revista: PATOLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Óseas / Tumor Óseo de Células Gigantes / Denosumab / Antineoplásicos Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Hum Pathol Asunto de la revista: PATOLOGIA Año: 2017 Tipo del documento: Article Pais de publicación: Estados Unidos